Join our daily newsletter At The Bell to receive exclusive market insights
- 4DMedical (4DX) is awarded $1.1 million in funding from the Federal Minister for Health and Aged Care
- The funds will aid the expansion of 4DX’s XV scanner capabilities beyond ventilation to measure blood flow
- Some advantages of this include improved patient experience, improved accessibility, rapid scan times, and low radiation
- 4DX’s XV Scanner was unveiled last year as the first dedicated lung scanner, using the company’s technology to provide a highly visual insight into lung function
- Shares are up 4.38 per cent at 71.1 cents at 11:31 am AEST
4DMedical (4DX) has been awarded $1.1 million in funding from the Federal Minister for Health and Aged Care.
The company announced the non-diluted funds are to be received as part of the Clinical Translation and Commercialisation Medtech (CTCM) Program, enabling the expansion of XV scanner capabilities beyond ventilation to perfusion.
The money comes from the initiative, Medical Research Future Fund (MRFF), delivered by MTPConnect, supported by the Medical Device Partnering Program (MDPP) and the Medical Technology Association of Australia (MTAA).
4DMedical’s XV Scanner was unveiled last year as the first dedicated lung scanner, using the company’s technology to provide a highly visual insight into lung function.
The funding will allow the company to expand the technology beyond ventilation, such as measuring the flow of blood.
This will help 4DMedical to be a world leader in non-invasive lung diagnostics by providing detailed quantitative data on respiratory function by a single scan.
Some advantages of this will include improved patient experience, improved accessibility, rapid scan times, and low radiation.
“Combining both functional components of airflow and blood flow into a single analytical process represents a dramatic advancement in respiratory healthcare, providing the ideal test for phenotyping, early detection and evaluation of specific treatment responses for high-impact lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, pulmonary hypertension and pulmonary embolism,” 4DX Managing Director and CEO Dr Andreas Fouras said.
The funding will also help make the technology more accessible to all patients.
4DX was up 4.38 per cent at 71.1 cents at 11:31 am AEST.
